More stories

  • in

    Here’s the deflation breakdown for August 2024 — in one chart

    Deflation, contrary to inflation, is when prices fall for certain goods and services.
    Deflation tends not to occur across the overall U.S. economy outside of recessions.
    However, consumer prices have fallen in some categories, such as cars, household furniture and appliances, airfare, and certain groceries since August 2023, according to the consumer price index.

    D3sign | Moment | Getty Images

    Inflation cooled in August and fell to its lowest level since February 2021, which was around the time the consumer price index began to climb during the pandemic era.
    This broad trend in the U.S. economy — a declining but still-positive rate of inflation — is known as “disinflation.” It means that, in aggregate, the average prices of goods and services are rising, just more slowly.

    However, there are also pockets of “deflation.” Their inflation rate is negative, meaning prices are falling.

    Deflation has largely been happening for physical goods such as cars and household appliances, though it has also appeared in categories such as gasoline and various groceries over the past year, according to the consumer price index.
    That said, consumers shouldn’t expect — or root for — a broad and sustained fall in prices across the U.S. economy. That generally doesn’t happen unless there’s a recession, economists said.

    ‘A huge shift in demand’

    Prices for “core” goods — commodities excluding those related to food and energy — have deflated by about 2% since August 2023, on average, according to CPI data.
    They fell 0.2% during the month, from July to August 2024.

    The dynamic of falling goods prices has largely been due to a “normalization” of supply-and-demand trends that were thrown out of whack during the pandemic, said Stephen Brown, deputy chief North America economist at Capital Economics.
    Demand for physical goods soared in the early days of the Covid-19 pandemic as consumers were confined to their homes and couldn’t spend on things such as concerts, travel or dining out. Households also had more discretionary income due to the pullback on spending coupled with federal aid.
    More from Personal Finance:Social Security cost-of-living increase could be lowest since 2021Why it’s not always ‘a sexy thing’ to be a millionaireThe ‘vibecession’ is ending
    “We saw a huge shift in demand, in terms of the type of things people were spending on, where you weren’t going out as much,” said Sarah House, senior economist at Wells Fargo Economics.
    The pandemic also snarled global supply chains, meaning goods weren’t hitting the shelves as quickly as consumers wanted them.
    Such supply-and-demand dynamics drove up prices.
    However, those economic contortions have largely eased and prices have deflated as a result, economists said.

    Where prices have deflated

    For example, prices have declined by about 5% for furniture and bedding and 3% for appliances since August 2023, according to CPI data.
    They’ve also fallen for tools, hardware and outdoor equipment, which are down 3%, toys, down 3%, and apparel, such as men’s suits and outerwear, down 10%, women’s outerwear, down 9%, and footwear, down 1%.
    Prices for new and used vehicles have fallen by 1% and 10%, respectively, since August 2023. Car and truck rental prices have deflated about 8%.

    Car prices were among the first to surge when the economy reopened broadly early in 2021, amid a shortage of semiconductor chips essential for manufacturing.
    Recent declines in car prices are largely due to “the inventory picture being more improved in the overall vehicle space,” House said. Higher financing costs have also reduced consumer demand, economists said.
    Outside of supply-demand dynamics, the U.S. dollar’s strength relative to other global currencies has also helped rein in prices for goods, economists said. This makes it less expensive for U.S. companies to import items from overseas, since the dollar can buy more.

    Long-term forces such as globalization have also helped, by increasing imports of more lower-priced goods from China, economists said.
    Airline fares have declined about 1% over the past year, according to CPI data.
    The drop is partly attributable to a decline in jet fuel prices, Capital Economics’ Brown said.
    Average aviation jet fuel prices are down about 21% from last year, according to the International Air Transport Association.
    Grocery prices have fallen for items such as apples, potatoes, ham, coffee, rice, seafood and bananas, according to CPI data. Each grocery item has its own supply-and-demand dynamics that can influence pricing, economists said.

    Other categories’ deflationary dynamics may be happening only on paper.
    For example, in the CPI data, the Bureau of Labor Statistics controls for quality improvements over time. Electronics such as televisions, cellphones and computers continually get better, meaning consumers generally get more for the same amount of money.
    That shows up as a price decline in the CPI data. More

  • in

    UAW, U.S. dealers increase criticism of Stellantis CEO over cuts, sales declines

    Stellantis’ U.S. dealer network has joined the United Auto Workers union in criticizing CEO Carlos Tavares for recent sales declines, factory production cuts and other decisions.
    The head of Stellantis’ U.S. dealer council condemned Tavares for prioritizing the company’s profits at the cost of sales, market share and the reputations of its American brands.
    The UAW is holding a rally Thursday afternoon near Stellantis’ Warren Truck Plant in suburban Detroit to “condemn the gross mismanagement” at the company.

    Carlos Tavares, CEO of Stellantis, poses during a presentation at the New York International Auto Show in Manhattan, New York, on April 5, 2023.
    David Dee Delgado | Reuters

    DETROIT – Stellantis’ U.S. dealer network has joined the United Auto Workers union in criticizing CEO Carlos Tavares for the company’s recent sales declines, factory production cuts and other decisions they deem detrimental to the automaker’s business.
    In an open letter to Tavares this week, the head of Stellantis’ U.S. dealer council, Kevin Farrish, condemned the chief executive for prioritizing the company’s profits at the cost of sales, market share and the reputations of its Chrysler, Dodge, Jeep and Ram brands. The council represents the company’s 2,600 U.S. dealers.

    “The market share of your brands has been slashed nearly in half, Stellantis stock price is tumbling, plants are closing, layoffs are rampant, and key executives fleeing the company. Investor lawsuits, supplier lawsuits, strikes–the fallout is mounting. Your own distribution network, your dealer body, has been left in an anemic and diminished state,” Farrish wrote in the Tuesday letter, which Bloomberg first reported Wednesday night.
    Farrish, a dealer in Virginia, said the dealer council has raised concerns about the company’s operations for two years, and accused Tavares of “reckless short-term decision making” that boosted profits and padded his compensation but have led to the “rapid degradation” of its brands, he wrote.

    Stock chart icon

    Stocks of Stellantis, GM and Ford

    Stellantis, in a statement Wednesday night, said it takes “absolute exception to the letter,” citing a 21% increase in August sales over July and an “action plan developed with the dealer body.”
    “At Stellantis, we don’t believe that public personal attacks, such as the one in the open letter from the NDC president against our CEO, are the most effective way to solve problems,” the company said. “We have started a path that will prove successful. We will continue to work with our dealers to avoid any public disputes that will delay our ability to deliver results.”
    Stellantis reported a record profit in 2023, but so far this year, the automaker reported a first-half net profit of 5.6 billion euros ($6.07 billion), down 48% from the same period of 2023.

    Shares of Stellantis are off roughly 36% this year to around $15. The stock hit a new 52-week low Thursday of $14.76 per share.
    Tavares has been on a profit-driven, cost-cutting mission since the company was formed through a merger between Fiat Chrysler and France’s PSA Groupe in January 2021. It’s part of his “Dare Forward 2030” plan to increase profits and double revenue to 300 billion euros ($325 billion) by 2030.
    The cost-saving measures have included reshaping the company’s supply chain and operations as well as headcount reductions and cutting vehicle production at plants.

    United Auto Workers (UAW) President Shawn Fain speaks to the attendees during a campaign rally for U.S. Vice President and Democratic Presidential candidate Kamala Harris and her running mate Tim Walz in Romulus, Michigan, U.S., August 7, 2024. 
    Rebecca Cook | Reuters

    Several Stellantis executives described the earlier cuts to CNBC as difficult but effective. Others, who spoke on the condition of anonymity due to potential repercussions, said they were grueling to the point of excessiveness.
    UAW President Shawn Fain also has publicly criticized Tavares, including in a speech last month at the Democratic National Convention. He has accused Tavares of price gouging consumers and failing to uphold parts of the union’s labor contract with the automaker.
    The UAW, which represents roughly 38,000 Stellantis employees, is holding a rally Thursday afternoon at a union hall near Stellantis’ Warren Truck Assembly Plant in suburban Detroit to “condemn the gross mismanagement” at the company, according to an email.
    U.S. sales for Stellantis, formerly Fiat Chrysler, have declined every year since a recent peak of 2.2 million in 2018. The company sold more than 1.5 million vehicles last year, a roughly 1% decline from 2022, when it reported a significant drop of 13% compared with the previous year.
    Stellantis’ performance compares to the overall U.S. new light-duty vehicle sales market, which increased 13% last year, according to federal data. More

  • in

    Airbus Ventures launches $155 million fund focused on deep tech, including space

    Airbus Ventures, one of the most prolific investors in space startups, has raised a $155 million fund.
    “This fund is designed to unlock new possibilities, and space is one of them,” Thomas d’Halluin, managing partner of Airbus Ventures, told CNBC.
    Airbus Ventures currently has $465 million under management, with Fund-Y marking its fourth fund to date. 

    Thomas d’Halluin, managing partner of Airbus Ventures, at Hangar One of NASA Ames Research Center’s Moffett Field in California.
    Airbus Ventures

    Airbus Ventures, one of the most prolific investors in space startups, has raised a $155 million fund that it plans to deploy across the burgeoning space sector, as well as the broader “deep tech” ecosystem.
    “This fund is designed to unlock new possibilities, and space is one of them,” Thomas d’Halluin, managing partner of Airbus Ventures, told CNBC.

    The move comes as investment in the space industry, especially from venture capital, has been rebounding after two lean years.
    Airbus Ventures’ new “Fund-Y” is targeting long-term opportunities in early-stage deep tech startups, which d’Halluin defines as “going back to the laws of physics and not being afraid of what’s difficult.” Historically, deep tech is a classification for companies working on technologies that face steep scientific or engineering obstacles.

    Read more CNBC space news

    Founded in 2016, Airbus Ventures takes a different tack from traditional corporate venture capital arms. The firm maintains a gap from its eponymous corporation, the European aerospace company, and more than half of Fund-Y comes from outside capital such as institutional investors, private equity and family offices. 
    Airbus Ventures currently has $465 million under management, with Fund-Y marking its fourth fund to date. 
    About a third of Airbus Ventures’ capital deployed so far has been in the space sector, the firm said, backing 14 pure-play companies in the sector, with notable investments including propulsion startup Impulse, lunar cargo company ispace and tracking service LeoLabs.

    “This is about patience. Often, and too often, people want immediate reward. Space is not a place of immediate reward,” d’Halluin said.

    The booster of SpaceX’s Falcon 9 rocket lands on the company’s barge after launching the Spaceflight SSO-A mission.

    He emphasized the importance of funding founders with the “extremely rare” trait of great execution, highlighting Airbus Ventures’ backing of Impulse. The startup was founded by Tom Mueller, best known for developing SpaceX’s family of rocket engines.
    “Impulse was successful on its first mission because of the 17 years of experience of Tom at SpaceX,” d’Halluin said.
    “That element of human capital we see often neglected in deep tech diligence — this notion of who’s capturing the execution and the knowledge and the skill set in a particular company — is what we’re pointing towards,” he added.
    While Airbus Ventures has traditionally deployed the majority of its funds in the U.S., d’Halluin said it intends for Fund-Y to be global. In particular, he sees “very strong momentum” for space startups in Europe and Japan.

    Don’t miss these insights from CNBC PRO More

  • in

    Gilead says its twice-yearly shot cut HIV infections by 96% in trial

    Gilead’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said.
    The data sets the stage for likely FDA approval of lenacapavir for HIV prevention.
    Shares rose 3% in premarket trading.

    A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug.
    Nardus Engelbrecht | AP

    Gilead’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.
    The positive phase-three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention.

    “Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP,” said Gilead CEO Daniel O’Day in a statement.
    PrEP or, pre-exposure prophylaxis, is medication taken to prevent getting HIV, according to the Centers for Disease Control and Prevention.
    Gilead shares climbed more than 1% on Thursday.
    The company said 99.9% of participants who received lenacapavir did not acquire HIV, with two cases among 2,180 people. The trial included cisgender men, transgender men, transgender women and gender non-binary people who have sex with partners assigned male at birth.
    There were nine cases of HIV in a group of more than 1,000 people assigned to receive Truvada, Gilead’s older daily pill used for prevention and treatment. The company said lenacapavir was 89% more effective than Truvada in the study. 

    Lenacapavir and Truvada were also “generally well-tolerated” by patients with no new safety concerns, according to Gilead. The drugmaker plans to present detailed data at an upcoming medical conference. 
    Gilead in June also said lenacapavir was 100% effective at preventing HIV in another late-stage trial with cisgender women. None of the approximately 2,000 women in the study who received the shot had contracted HIV by the time of an interim analysis conducted in September 2023. 
    In a research note Thursday, Jefferies analyst Michael Yee said overall the data on lenacapavir is “solid and consistent across both studies” and populations.
    The trial results should lead to an FDA approval and launch in the market by 2025, Yee said. 
    Subscribe to CNBC on YouTube. More

  • in

    Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027

    Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business. 
    The biotech company said it expects 10 new product approvals through 2027.
    But Moderna is also deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

    Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. 
    Plexi Images | GHI | UCG | Universal Images Group | Getty Images

    Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. 
    The biotech company said it expects 10 new product approvals through 2027. But Moderna said it will also pause work on some products in its pipeline and scrap others, as it aims to “pace ourselves” in new research and development spending. 

    The company aims to trim R&D spending to a range of $3.6 billion to $3.8 billion in 2027, down from an expected $4.8 billion at the end of this year, according to a release.
    “You’re going to start seeing things come down because there are some studies that we are going to basically sunset and we’re not going to start,” Moderna CEO Stephane Bancel told CNBC, adding that the company is putting its latent product portfolio “on hold.” That refers to a category of viruses that linger inside patients for prolonged periods without causing any symptoms but can reactivate and cause serious health complications later in their lives. 
    Still, shares of Moderna fell more than 14% in premarket trading Thursday.
    Leerink Partners analyst Mani Foroohar said in an email Thursday that the company’s updates “put to rest key elements of the bull thesis” for its stock and “reflect a worsening financial position.”
    “R&D reductions are too far out chronologically to be credible from a management team that we think has proven serially unable to project the performance of their business,” Foroohar said.

    In a research note Thursday, Jefferies analyst Michael Yee said that the bulk of the cost savings won’t be achieved until 2027, which “now delays profitability until 2028.”
    Also on Thursday, Moderna announced positive late-stage trial results on its vaccine against respiratory syncytial virus in high-risk adults ages 18 to 59, with plans to file for approval for that age group this year. It also announced positive data on its experimental standalone flu shot for adults ages 65 and older. 
    The company unveiled those updates during its annual research and development day investor event in New York on Thursday, which focuses on its product pipeline and long-term business updates. It comes around four months after U.S. regulators cleared Moderna’s RSV vaccine for seniors, its second commercially available product after its Covid vaccine. 
    The company said it now has five respiratory shots with positive phase three results and expects to submit three of those jabs for approval this year. That includes Moderna’s combination shot targeting Covid and the flu, which it expects to file for approval in the U.S. this year, along with a new and more effective version of its Covid shot. 
    Moderna also has five non-respiratory products across cancer, latent viruses and rare diseases that could be approved by 2027, according to the company’s release. 
    The company expects 2025 revenue to come in at $2.5 billion to $3.5 billion. From 2026 to 2028, Moderna expects a compounded annual growth rate of more than 25% as new products launch. 
    Bancel said the company’s rate of success for developing drugs from phase one to phase three is “six times higher” than the rest of the biotech and pharmaceutical industry. 
    “That’s really a remarkable achievement that the team has accomplished, leaving us with a lot of drugs that are working, which is why need to pace ourselves in terms of R&D investment,” he told CNBC. 

    What’s in Moderna’s pipeline?

    Moderna presented new data on its RSV vaccine, mRESVIA, which is cleared in the U.S. and European Union for adults 60 and above. 
    The company said the shot met all of the main efficacy goals in an ongoing phase three study on adults ages 18 to 59 who are at increased risk of getting severely sick from the virus. There were no safety concerns observed, Moderna added.
    There are currently no RSV shots approved worldwide for younger, high-risk adults, such as those with weakened immune systems or underlying chronic conditions like asthma and diabetes. Moderna’s main rivals in the RSV space, Pfizer and GSK, are also seeking an expanded approval for the age group. 

    Moderna CEO Stephane Bancel speaks at the grand opening of the company’s new headquarters outside Kendall Square.
    David L. Ryan | Boston Globe | Getty Images

    Bancel said the company plans to use a “priority review voucher” when it files for approval for people ages 18 to 59, which would reduce the amount of time it takes for the Food and Drug Administration to review the product to six months instead of 10 months. Moderna hopes the agency will clear mRESVIA for that age group in time for the RSV season in 2025. 
    “It’s in the millions of people who could benefit … We are also doing so just to be competitive in the marketplace because if you are a large retail pharmacy, you want your product to be available for all of your customers that show up,” Bancel said. 
    But the company is also discontinuing development of its RSV vaccine for infants under 2 years old based on “emerging clinical data.” 
    Moderna said its experimental standalone flu vaccine, mRNA-1010, produced a higher immune response against the virus compared to an existing flu shot in a recent phase three trial. The shot has also demonstrated “consistently acceptable safety and tolerability” across three late-stage trials, the company added.
    Meanwhile, Moderna said it plans to move its shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea, to a phase three trial “imminently.” Bancel said he believes the company could finish the study within a year and file for approval immediately after if the data is positive. 
    “This could be a product that is two years away from launch, which is great because there’s nothing today to treat norovirus,” he said. “A lot of healthcare professionals get infected by their patients.”
    Moderna is also partnering with Merck to develop a personalized cancer vaccine, which is being studied in combination with Keytruda in patients with different forms of the disease. 
    The companies are studying the shot in a phase three trial in patients with a deadly skin cancer and discussing an approval with regulators based on data from a mid-stage study on the jab.
    But Moderna said the FDA has “not been supportive” of a so-called accelerated approval of the shot based on its existing data. That refers to an FDA designation that clears drugs faster if they fill an unmet medical need for serious conditions.
    Bancel said “we’re going to keep having discussions” with regulators, and “we’re also generating more data.”
    — CNBC’s Angelica Peebles contributed to this report More

  • in

    Boeing faces strike threat as workers vote on new contract

    Boeing and the union that represents some 33,000 workers unveiled a tentative agreement earlier this week.
    The deal would include 25% raises over four years.
    The current contract expires after midnight in Washington on Thursday.

    A Boeing 737 MAX aircraft is assembled at the Boeing Renton Factory in Renton, Washington, on June 25, 2024.
    Jennifer Buchanan | Afp | Getty Images

    Boeing workers are voting on a new labor contract on Thursday, setting up the potential for a crippling strike if staff members decide to reject the deal just as the plane-maker is trying to ramp up its production.
    The tentative agreement that the International Association of Machinists and Aerospace Workers and the company unveiled on Sunday included 25% wage increases and other improvements to health-care and retirement benefits. Boeing also committed to build its next aircraft in the Seattle area.

    The vote is the first major test for CEO Kelly Ortberg, who said in a staff note on Wednesday that he has talked with employees about the contract in Renton, Washington, and Everett, Washington, where Boeing’s main factories are located.
    Ortberg is just over one month into his role in the manufacturer’s top job, and has been tasked with steadying production and stamping out safety lapses and quality flaws in the wake of a door-panel blowout at the start of the year.
    “I know the reaction to our tentative agreement with the IAM has been passionate,” he wrote in his staff note. “I understand and respect that passion, but I ask you not to sacrifice the opportunity to secure our future together, because of the frustrations of the past.”
    The union, which represents about 33,000 Boeing factory workers in the Seattle area and in Oregon had sought some 40% pay raises from Boeing. But the 25% increase would be in line with the United Auto Workers’ deal last year that followed strikes at Ford, General Motors and Chrysler-parent Stellantis.
    If approved, the Boeing deal would follow a series of union-negotiated pay increases across industries ranging from Hollywood to airlines.

    “We have achieved everything we could in bargaining, short of a strike,” IAM District 751 district president Jon Holden wrote to members on Monday. “We recommended acceptance because we can’t guarantee we can achieve more in a strike. But that is your decision to make and is a decision that we will protect and support, no matter what.”

    Read more CNBC airline news

    Top pay for IAM workers at Boeing would rise to $57.43 an hour as soon as the new contract goes into effect. Including some cost-of-living adjustments, increases could rise by more than 42%, according to the union. Boeing said average annual machinist pay is currently $75,608, which would rise to $106,350 at the end of the four-year contract.
    If the deal is rejected and two-thirds of workers vote in favor of a strike, a work stoppage would begin after midnight in Washington on Friday. If less than two-thirds vote to strike after the contract is rejected, the contract would automatically go into effect, the union said.
    “For Boeing, it is no secret that our business is in a difficult period, in part due to our own mistakes in the past,” Ortberg said in his note. “Working together, I know that we can get back on track, but a strike would put our shared recovery in jeopardy, further eroding trust with our customers and hurting our ability to determine our future together.”
    Polls are set to close at 6 p.m. PT.

    Don’t miss these insights from CNBC PRO More

  • in

    CEO of Ford’s highly profitable Pro business to retire

    The head of Ford’s highly profitable “Pro” commercial and fleet business will retire at the end of this month, the company said Thursday.
    The automaker said Ford Pro CEO Ted Cannis will be replaced on an interim basis by Andrew Frick, president of Ford’s traditional “Blue” operations.

    Ted Cannis, chief executive officer of Ford Pro, speaks during an interview in New York, on Thursday, July 28, 2022.
    Victor J. Blue | Bloomberg | Getty Images

    DETROIT — The head of Ford Motor’s highly profitable “Pro” commercial and fleet business will retire at the end of this month, the company said Thursday.
    The automaker said Ford Pro CEO Ted Cannis, who has spent 35 years with the company, will be replaced on an interim basis by Andrew Frick, president of Ford’s traditional “Blue” operations, until the company announces a new leader.

    “Ted’s energy and passion for customers has been instrumental in building Ford Pro into a business that’s tracking towards $70 billion in revenue this year – a Fortune 100-size company in its own right,” Ford CEO Jim Farley said in a statement.
    Ford Pro has been a profit-driver for the automaker. It has raked in about $18.7 billion in adjusted earnings and $184.5 billion in revenue since 2021, assisting in offsetting losses of its electric vehicles business.
    Such results led Wall Street to praise the business, as analysts have called it a “hidden gem” and Ford’s “Ferrari,” referring to the highly profitable Italian sports car manufacturer.

    Cannis also led Ford Customer Service Division, which handles global parts, services, accessories and vehicle customization for Ford dealers and customers worldwide.
    Daniel Justo, who currently serves as chief financial office of Ford Blue, will begin overseeing the operations upon Cannis’ retirement.
    “It’s been the most thrilling and rewarding chapter of my career to lead Ford Pro and FCSD,” Cannis said in a release. “Ford Pro is a profitably growing business with unmatched scale, talent, and the best dealers and upfitters – all to serve the people and businesses who keep our economy and communities humming. I can’t wait to watch Ford Pro and FCSD continue to innovate and grow.” More

  • in

    Ajit Jain, Buffett’s insurance leader for nearly 40 years, dumps more than half of Berkshire stake

    Ajit Jain at Berkshire Hathaway’s annual meeting in Los Angeles, California. May 1, 2021.
    Gerard Miller | CNBC

    Ajit Jain, Warren’s Buffett’s insurance chief and top executive, sold more than half of his stake in Berkshire Hathaway, a new regulatory filing showed.
    The 73-year-old vice chairman of insurance operations dumped 200 shares of Berkshire Class A shares on Monday at an average price of $695,418 per share for roughly $139 million. That left him holding just 61 shares, while family trusts established by himself and his spouse for the benefit of his descendants hold 55 shares and his non-profit corporation Jain Foundation owns 50 shares. Monday’s sale represented 55% of his total stake in Berkshire.

    The move marked the biggest decline in Jain’s holdings since he joined Berkshire in 1986. It’s unclear what motivated Jain’s sales, but he did take advantage of Berkshire’s recent high price. The conglomerate traded above $700,000 to hit a $1 trillion market capitalization at the end of August.
    “This appears to be a signal that Ajit views Berkshire as being fully valued,” said David Kass, a finance professor at the University of Maryland’s Robert H. Smith School of Business. 

    Stock chart icon

    Berkshire Hathaway

    It’s also consistent with a significant slowdown in Berkshire’s share buyback activity as of late. Omaha-based Berkshire repurchased just $345 million worth of its own stock in the second quarter, significantly lower than the $2 billion repurchased in each of the prior two quarters.
    “I think at best it is a sign that the stock is not cheap,” said Bill Stone, CIO at Glenview Trust Company and a Berkshire shareholder. “At over 1.6 times book value, it is probably around Buffett’s conservative estimate of intrinsic value. I don’t expect many, if any, stock repurchases from Berkshire around these levels.”
    The India-born Jain has played a crucial role in Berkshire’s unmatched success. He facilitated a push into the reinsurance industry and more recently led a turnaround in Geico, Berkshire’s crown jewel auto insurance business. In 2018, Jain was named vice chairman of insurance operations and appointed to Berkshire’s board of directors.

    “Ajit has created tens of billions of value for Berkshire shareholders,” Buffett wrote in his annual letter in 2017. “If there were ever to be another Ajit and you could swap me for him, don’t hesitate. Make the trade!”
    Before it was officially announced that Greg Abel, Berkshire’s vice chairman of non-insurance operations, will evenetually succeed the 94-year-old Buffett, there were rumors about Jain one day leading the conglomerate. Buffett recently clarified that Jain “never wanted to run Berkshire” and there wasn’t any competition between the two. More